New and emerging drugs in type 2 diabetes / 대한내과학회지
Korean Journal of Medicine
;
: 446-450, 2007.
Article
Dans Coréen
| WPRIM
| ID: wpr-162636
ABSTRACT
Recent advances in understanding insulin secretion, action and signaling have led to the development of new pharmacological agents. Several new emerging drugs and drug classes for the management of diabetes are under development, including the incretin mimetic agents (exenatide, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide 1 analogues), the amylin analogue pramlintide, the cannabinoid-1 receptor antagonist rimonabant, the mixed peroxisome proliferator-activated receptor agonists muraglitazar and the inhaled insulin preparation Exubera. New drugs and technologic advances being made available will help achieve the goals of treating patients with diabetes to all the appropriate metabolic targets. Longer term studies will help providers weigh the benefits, adverse effects, cost, and unknown long-term risks of these medications.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Péroxysomes
/
Glucagon-like peptide 1
/
Inhibiteurs de la dipeptidyl-peptidase IV
/
Incrétines
/
Polypeptide amyloïde des ilots
/
Insuline
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Korean Journal of Medicine
Année:
2007
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS